According to the proposed interference of N-acetylcysteine ( NAC ) with pathophysiologic processes of autistic disorders ( ADs ) , we aimed to assess the effectiveness and safety of NAC as an adjunct to risperidone in the treatment of ADs in a randomized , double-blind , clinical trial .